Overview
Antleron helps innovators design, optimize, and scale controlled bioprocesses with precision, speed, and reliability. The company accelerates therapy development and fine-tunes complex workflows through data-driven insight and scalable engineering.
Key people
In the news
- Every autologous CAR-T batch starts from a different patient’s T cells. That donor variability is one of the main reasons batches miss their release specifications. At Science for health on 10 November, our process engineer and data scientist Evan Claes presents a poster on bringing those batches back in spec. In the case study behind it, the digital twin enabled out-of-spec batches dropping from 18.4% with the default process to 5.4% when patients are stratified into a few subgroups with pre-approved settings. The approach
- Your fixed-bed bioreactor is full of cells you cannot count, not without stopping the run, breaking open the bed, and destroying it in the process. What if you could get a reliable estimate continuously, straight from data the bioreactor is already generating? That is the idea behind soft sensing in Antleron Nexus. We combine process signals you already track (glucose, lactate, oxygen consumption) to estimate something that is otherwise nearly impossible to measure in-line. The output: a live cell density estimate, with confidence
- Precision medicine promises therapies made for one patient. Each of them still has to be manufactured, from starting material that is different every time. Our CEO Jan Schrooten and Evan Claes will be at Science for health 2026 in Brussels on 10 November. This edition, Immunology reengineered, brings researchers, clinicians and industry together around the next generation of immune therapies, from CAR-T to engineered antibodies. Making sure a process is ready for manufacturing, that is where Antleron steps in. With scaled-down
- An EV process that works once is not the same as an EV process that works every time. Getting from the first to the second is where most of the work sits between discovery and a clinical batch. We are in Berlin this week for Exosomes Europe 2026. Our co-founder and CEO Jan Schrooten opens day two on Thursday 5 November at 09:05 with "Smart EV Biomanufacturing: Balancing Yield, Purity & Scale from Lab to Clinic", the first talk of the downstream purity and quality control track. Three things we want to discuss while we are there: •
- Scale-up rarely creates a new problem. It usually exposes one that was already there at bench scale, just never measured. Our co-founder and CEO Jan Schrooten will be at CELL 2026 in London on 12 and 13 November, NextGen Biomed by Oxford Global's meeting for bioprocessing and cell and gene therapy manufacturing. Finding those problems early is the work we do at Antleron. With scaled-down models in the lab and hybrid models in silico, we help developers see how their process will behave at the next scale, before they commit
- 𝙃𝙖𝙣𝙙 𝙮𝙤𝙪𝙧 𝙥𝙧𝙤𝙘𝙚𝙨𝙨 𝙙𝙖𝙩𝙖 𝙩𝙤 𝙖𝙣 𝙚𝙭𝙩𝙚𝙧𝙣𝙖𝙡 𝙥𝙖𝙧𝙩𝙣𝙚𝙧 𝙖𝙣𝙙 𝙤𝙣𝙚 𝙦𝙪𝙚𝙨𝙩𝙞𝙤𝙣 𝙘𝙤𝙢𝙚𝙨 𝙪𝙥 𝙖𝙡𝙢𝙤𝙨𝙩 𝙚𝙫𝙚𝙧𝙮 𝙩𝙞𝙢𝙚: 𝙬𝙝𝙤 𝙤𝙬𝙣𝙨 𝙬𝙝𝙖𝙩 𝙘𝙤𝙢𝙚𝙨 𝙤𝙪𝙩 𝙤𝙛 𝙞𝙩? Fair question, and it deserves a precise answer. The model we build for you and deploy on Antleron Nexus is built entirely on your process data and your biological context. It is yours exclusively, never shared or reused across clients. The expertise we apply to build it is ours to bring to every client, but
- The questions you need answered on day one of your CGT program are not the ones you will be asking at tech transfer, but they can run on the same model. Early on, you are exploring and building understanding. Later, you are defining and tightening your design space for manufacturing. The hybrid model we build for you and deploy on Antleron Nexus is designed to serve both, and everything in between. It does not power a single tool you use once and shelve. It becomes the engine behind a growing set of applications your team can use
- 𝗪𝗵𝗲𝗿𝗲 𝗱𝗼𝗲𝘀 𝘆𝗼𝘂𝗿 𝗽𝗿𝗼𝗰𝗲𝘀𝘀 𝗱𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝘀𝘁𝗮𝗹𝗹? We would like to hear your answer in our short survey. It takes only a few minutes, and the link is in the comments. This week our team is at ESGCT, asking people in cell and gene therapy the same questions in person. If we don’t get to meet you there, the survey link works just as well. At Antleron we combine a physical scaled-down model of a client’s process with a custom hybrid process model. Through Antleron Nexus, these models become web-based
Related profiles
Something wrong or missing? Send an update. Fixed within 24 hours.